LTX-315 + pembrolizumab

DRUG2 trials

Sponsors

Lytix Biopharma AS, Oslo University Hospital

Conditions

Breast CancerCancerHead and Neck CancerLymphomaMelanomaMelanoma Stage IIIB-IVTriple-Negative Breast Cancer

Phase 1

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

CompletedNCT01986426

Lytix Biopharma ASBreast Cancer, Cancer, Head and Neck Cancer +3

Start: 2013-11-30End: 2018-08-31Target: 80Updated: 2018-10-03

Phase 2

NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma

RecruitingNCT06651151

Oslo University HospitalMelanoma Stage IIIB-IV

Start: 2024-11-01End: 2031-05-31Target: 27Updated: 2024-10-26

Related Papers

Safety and efficacy of intratumoral (IT) ruxotemitide (LTX 315) in combination with pembrolizumab in patients with unresectable advanced melanoma or triple-negative breast cancer (TNBC).

Journal of Clinical Oncology2026-05-27

LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma

OncoImmunology2023-12-0731 citations

560 Immunotherapeutic and antimetastatic activity of LTX-315 in preclinical models of ICI-resistant breast cancer

Regular and Young Investigator Award Abstracts2021-11-01

Abstract CT010: A phase I study of the oncolytic peptide LTX-315 generates<i>de novo</i>T-cell responses and clinical benefit in patients with advanced sarcoma

Cancer Research2019-07-013 citations

Abstract CT069: A Phase I study of the oncolytic peptide LTX-315 generates <i>de novo</i> T-cell responses and clinical benefit in patients with advanced melanoma

Cancer Research2019-07-012 citations

Abstract CT069: A Phase I study of the oncolytic peptide LTX-315 generates<i>de novo</i>T-cell responses and clinical benefit in patients with advanced melanoma

Clinical Trials2019-07-011 citations

Abstract CT010: A phase I study of the oncolytic peptide LTX-315 generates<i>de novo</i>T-cell responses and clinical benefit in patients with advanced sarcoma

Clinical Trials2019-07-01

Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report.

2019-06-1011 citations

A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates <i>de novo</i> T-cell responses and clinical benefit in patients with advanced solid tumors.

Journal of Clinical Oncology2018-05-2015 citations

Abstract CT108: A phase I dose escalation study of intra-tumoral LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab in patients with transdermally accessible tumors (NCT01986426)

Cancer Research2017-07-01

LTX-315, an oncolytic peptide, to convert immunogenically ‘cold' tumors to ‘hot' in patients with advanced or metastatic tumours: Results from an ongoing phase I study.

Journal of Clinical Oncology2017-05-207 citations